Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 15

recruiting
3 968
countries
28
conditions
2 103

584 trials match your criteria

Study of Carboplatin, Paclitaxel, and Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer After Pembrolizumab Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib

Study on Obinutuzumab vs. Rituximab for Children with Steroid-Dependent and Frequent Relapsing Nephrotic Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Obinutuzumab

Study of Asciminib treatment for patients with Chronic Myeloid Leukemia who have T315I mutation and cannot take or tolerate ponatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride

Comparison of ruxolitinib versus hydroxycarbamide or interferon alfa as first treatment for high-risk polycythemia vera patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxycarbamide

Seminoma

Recruiting

Study on Reducing Treatment for Stage IIa/IIb Seminoma Using Etoposide, Cisplatin, and Carboplatin in Patients with Tumors Smaller than 3 cm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin

Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide

Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.